Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells.

Lin-Ping Cao Chen Zhang Xiao-Yu Weng Hai-Yang Xie Jian Wu Shu-Sen Zheng

Hepatobiliary Pancreat Dis Int

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, China; The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310003, China. Electronic address:

Published: June 2020

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.hbpd.2020.03.003	DOI Listing

Publication Analysis

Top Keywords

synergistic interaction

interaction thioredoxin

thioredoxin inhibitor

inhibitor 1-methylpropyl

1-methylpropyl 2-imidazolyl

2-imidazolyl disulfide

disulfide sorafenib

sorafenib liver

liver cancer

cancer cells

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!